About Ashvattha Therapeutics
Ashvattha Therapeutics is a company based in Redwood City (United States) founded in 2015.. Ashvattha Therapeutics has raised $180.37 million across 8 funding rounds from investors including Tribe Capital, Plum Alley Investments and Huadong Medicine. Ashvattha Therapeutics offers products and services including Migaldendranib (MGB) and Hydroxyl Dendrimer Technology. Ashvattha Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Redwood City, United States
-
Sectors
TechnologyHealthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Ashvattha Therapeutics, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$180.37 M (USD)
in 8 rounds
-
Latest Funding Round
$50 M (USD), Series B
Jan 14, 2025
-
Investors
Tribe Capital
& 4 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ashvattha Therapeutics
Ashvattha Therapeutics offers a comprehensive portfolio of products and services, including Migaldendranib (MGB) and Hydroxyl Dendrimer Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapeutic targeting wet AMD and DME in ophthalmology.
Enables selective uptake by inflamed tissues for precision medicine.
Unlock access to complete
Unlock access to complete
Funding Insights of Ashvattha Therapeutics
Ashvattha Therapeutics has successfully raised a total of $180.37M across 8 strategic funding rounds. The most recent funding activity was a Series B round of $50 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Series B — $50.0M
-
First Round
First Round
(03 Mar 2016)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2025 | Amount | Series B - Ashvattha Therapeutics | Valuation | Tribe Capital , unknown |
|
| Apr, 2022 | Amount | Series B - Ashvattha Therapeutics | Valuation | Huadong Medicine | |
| Apr, 2021 | Amount | Series A - Ashvattha Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ashvattha Therapeutics
Ashvattha Therapeutics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Tribe Capital, Plum Alley Investments and Huadong Medicine. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in global seed and early-stage startups.
|
Founded Year | Domain | Location | |
|
Pharmaceutical products are manufactured and traded domestically and overseas.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ashvattha Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ashvattha Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ashvattha Therapeutics Comparisons
Competitors of Ashvattha Therapeutics
Ashvattha Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ashvattha Therapeutics
Frequently Asked Questions about Ashvattha Therapeutics
When was Ashvattha Therapeutics founded?
Ashvattha Therapeutics was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Where is Ashvattha Therapeutics located?
Ashvattha Therapeutics is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Who is the current CEO of Ashvattha Therapeutics?
Jeffrey L Cleland is the current CEO of Ashvattha Therapeutics.
Is Ashvattha Therapeutics a funded company?
Ashvattha Therapeutics is a funded company, having raised a total of $180.37M across 8 funding rounds to date. The company's 1st funding round was a Series A of $60.18M, raised on Mar 03, 2016.
What does Ashvattha Therapeutics do?
Developer of hydroxyl dendrimers therapeutics for the treatment of infectious diseases and cancer. It has developed hydroxyl dendrimers that target endocytosing cells such as reactive microglia and macrophages responsible for chronic inflammation and disease progression within the body. It provides an OP-101 product that targets reactive macrophages responsible for hyper inflammation leading to lung injury and multi-organ failure in severe COVID-19 patients. The other products include D-B483 for neuro-oncology, OP-801 for neuroinflammation, and D-4517 for ophthalmology diseases.
Who are the top competitors of Ashvattha Therapeutics?
Ashvattha Therapeutics's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
What products or services does Ashvattha Therapeutics offer?
Ashvattha Therapeutics offers Migaldendranib (MGB) and Hydroxyl Dendrimer Technology.
Who are Ashvattha Therapeutics's investors?
Ashvattha Therapeutics has 5 investors. Key investors include Tribe Capital, Plum Alley Investments, Huadong Medicine, unknown, and Natural Capital Investment Fund.